KEYTRUDA TREATMENT
Keytruda (pembrolizumab)
is a type of immunotherapy that is used to treat certain types of cancer. It is
a monoclonal antibody that works by binding to a protein called PD-1 on the
surface of T cells, which are a type of white blood cell that plays a key role
in the body's immune response. By binding to PD-1, Keytruda blocks the
interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are found on
the surface of cancer cells. This interaction normally acts as an "off
switch" for the T cell's immune response, allowing cancer cells to evade
the body's natural defenses. By blocking this interaction, Keytruda "turns
on" the T cell's immune response, allowing it to target and attack cancer
cells.
Keytruda
is FDA approved for treatment of several types of cancer such as Non-Small Cell
Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma,
Gastric cancer, Urothelial Carcinoma. It is also being studied in clinical
trials for the treatment of many other types of cancer.
The usual
treatment schedule for keytruda is an IV infusion every 3 weeks. The usual
dosage is 2 mg/kg body weight. The duration of treatment depends on the
individual patient, treatment response and the cancer type being treated. It's
usually given until the cancer progression or unacceptable side effects occur.
It's
important to consult with an experienced oncologist to determine if Keytruda is
an appropriate treatment option for a specific patient and disease. The
oncologist may also determine if any other treatments, such as chemotherapy or
radiation therapy, are needed in combination with Keytruda to achieve the best
results. Close monitoring of the patient's response to the treatment and
managing any side effects that may occur is essential.
KEYTRUDA SUCCESS RATE
The success rate of Keytruda (pembrolizumab)
varies depending on the type and stage of the cancer being treated, as well as
the overall health of the patient. In general, Keytruda has been shown to be
highly effective in treating a number of different types of cancer,
particularly those that are characterized by the expression of PD-L1 on the
surface of cancer cells.
In Non-Small Cell Lung Cancer, Keytruda has
shown to improve overall survival and progression free survival in certain
patient population such as those with high PD-L1 expression. In Head and Neck
Squamous Cell Carcinoma, Keytruda in combination with chemotherapy improved
overall survival and progression-free survival in patient population with high
PD-L1 expression.
In Classical Hodgkin Lymphoma, it has improved
complete response rate and progression-free survival rate when used as a
second-line therapy.
In Gastric Cancer, it has improved overall
survival and progression-free survival in patients with high PD-L1 expression.
In Urothelial Carcinoma, Keytruda in
combination with chemotherapy has shown improvement in overall survival and
progression-free survival.
It is important to note that the PD-L1
expression level is an important prognostic factor in determining the response
to treatment with Keytruda, therefore a detailed patient assessment and
pathology review is crucial to determine the appropriateness of treatment and
to predict the chances of a successful outcome.
Additionally, Keytruda is being tested in
clinical trials for many other types of cancer, and so far results have been
promising, however further research is needed to fully understand its efficacy
in those cancer types. It's important to note that individual patient's
response may vary and it's important to consult with a specialist to understand
what to expect from the therapy.
KEYTRUDA INDICATIONS
Keytruda (pembrolizumab) is an immunotherapy
drug that has been approved by the U.S. Food and Drug Administration (FDA) for
the treatment of several types of cancer. The specific indications for Keytruda
vary depending on the type of cancer being treated and the patient population.
Here are some of the key indications for Keytruda:
Non-Small Cell Lung Cancer (NSCLC): Keytruda
is approved for the treatment of patients with NSCLC whose tumors express high
levels of PD-L1 (a protein that helps cancer cells evade the immune system), as
determined by an FDA-approved test, and who have progressed on or after
platinum-containing chemotherapy.
Head and Neck Squamous Cell Carcinoma (HNSCC):
Keytruda is approved for the treatment of patients with HNSCC with recurrent or
metastatic disease, with or without chemotherapy, and with disease progression
on or after platinum-containing therapy.
Classical Hodgkin Lymphoma (cHL): Keytruda is
approved as a treatment option for adult and pediatric patients with relapsed
or refractory cHL after autologous hematopoietic stem cell transplantation
(HSCT) and post-transplantation brentuximab vedotin.
Gastric Cancer: Keytruda is approved for the
treatment of adult and pediatric patients with unresectable or metastatic
disease with PD-L1 expression (≥1%) as determined by an FDA-approved test.
Urothelial Carcinoma: Keytruda is approved for
the treatment of patients with locally advanced or metastatic urothelial
carcinoma who are not eligible for cisplatin-containing chemotherapy, who have
disease progression during or following platinum-containing chemotherapy, or
have disease progression within 12 months of neoadjuvant or adjuvant treatment
with platinum-containing chemotherapy.
It's important to note that the indication and
usage of Keytruda is subject to FDA approved language and indications may be
different depending on the country of use and the local regulatory agency.
Also, it is important to consult with an experienced oncologist to determine if
Keytruda is an appropriate treatment option for a specific patient and disease.
0 Comments